Perelman School of Medicine at the University of Pennsylvania

Penn Institute for Immunology

Jan Joseph Melenhorst

faculty photo
Adjunct Associate Professor of Pathology and Laboratory Medicine
Department: Pathology and Laboratory Medicine
Graduate Group Affiliations

Contact information
SPE South Tower, Rm. 9-105,
3400 Civic Center Boulevard, Blg. 421
Philadelphia, PA 19104-5156
Office: 215.573.6852
Lab: N/A
Education:
BSc (Biology, Geography, Associate Professor in Continuing Education)
Moller Institute, Netherlands, 1988.
MS (Medical Biology)
Nijmegen Katholic University, Netherlands, 1991.
PhD (Immunology)
Leiden University, Netherlands, 1998.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Clinical Expertise

As a translational immunologist my interest is in improving the potency and safety of adoptive immunogene therapy via correlative studies and product/process development. My translational interest also lies in streamlining the immunogene manufacturing process while maintaining or improving product potency.

Description of Other Expertise

Immunology of human allogeneic hematopoietic stem cell transplantation.

Description of Research Expertise

My expertise is in human T cell immunology and immunogene therapy, understanding and improving the anti-tumor efficacy of gene-engineered T cells for the treatment of cancers.

Selected Publications

Whitney JE, Zhang B, Koterba N, Chen F, Bush J, Graham K, Lacey S, Melenhorst JJ, Teachey DT, Mensinger JL, Yehya N, Weiss SL.: Endothelial Dysfunction is Associated with Acute Respiratory Distress Syndrome in Children with Extrapulmonary Sepsis, Critical Care Medicine. Critical Care Medicine 48(3): 344-352, 2020.

Nobles CL, Sherrill-Mix S, Everett JK, Reddy S, Fraietta JA, Porter DL, Frey N, Gill SI, Grupp SA, Maude SL, Siegel DL, Levine BL, June CH, Lacey SL, Melenhorst JJ+, Bushman FD+ : CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration. J Clin Invest 130(2): 673-685, 2020 Notes: + corresponding co-senior authors.

Frey NV, Shaw PA, Hexner EO, Pequignot E, Gill S, Luger SM, Mangan JK, Loren AW, Perl AE, Maude SL, Grupp SA, Shah NN, Gilmore J, Lacey SF, Melenhorst JJ, Levine BL, June CH, Porter DL.: Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. J Clin Oncol. 38(5): 415-422, 2020.

Stadtmauer, EA, Fraietta, JA, Davis, MM, Cohen, AD, Weber, KL, Lancaster, E, Mangan, PA, Kulikovskaya, I, Gupta, M, Chen, F, Tian, L, Gonzalez, VE, Xu, J, Jung, IY, Melenhorst, JJ, Plesa, G, Shea, J, Matlawski, T, Cervini, A, Gaymon, AL, Desjardins, S, Lamontagne, A, Salas-Mckee, J, Fesnak, A, Siegel, DL, Levine, BL, Jadlowsky, JK, Young, RM, Chew, A, Hwang, WT, Hexner, EO, Carreno, BM, Nobles, CL, Bushman, FD, Parker, KR, Qi, Y, Satpathy, AT, Chang, HY, Zhao, Y, Lacey, SF, June CH: CRISPR-engineered T cells in patients with refractory cancer. Science. 2020 Feb 6. pii: eaba7365. doi: 10.1126/science.aba7365. [Epub ahead of print] 2020.

Singh N, Orlando E, Xu J, Xu J, Binder Z, Collins MA, O'Rourke DM, Melenhorst JJ.: Mechanisms of resistance to CAR T cell therapies. Semin Cancer Biol. 2019 Dec 19. pii: S1044-579X(19)30398-0. doi: 10.1016/j.semcancer.2019.12.002. [Epub ahead of print] Review. Dec 2019.

Pillai V, Muralidharan K, Meng W, Bagashev A, Oldridge DA, Rosenthal J, Van Arnam J, Melenhorst JJ, Mohan D, DiNofia AM, Luo M, Cherian S, Fromm JR, Wertheim G, Thomas-Tikhonenko A, Paessler M, June CH, Luning Prak ET, Bhoj VG, Grupp SA, Maude SL, Rheingold SR.: CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy. Blood Adv 3(22): 3539-3549, Nov 2019 Notes: doi: 10.1182/bloodadvances.2019000692.

Stadtmauer EA, Cohen AD, Weber K, Lacey SF, Gonzalez VE, Melenhorst JJ, Fraietta JA, Plesa G, Shea J, Matlawski T, Cervini A, Mangan P, Gaymon A, Desjardins S, Lancaster E, Salas-Mckee J, Suhoski MM, Fesnak A, O'Rourke M, Lamontagne A, Siegel DL, Young RM, Chew A, Nobles CL, Bushman FD, Chang HY, Satpathy AT, Zhao Y, Hwang WT, Hexner EO, June CH.: First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma. Blood 134(Supplement_1): 49, Nov 2019 Notes: doi: 10.1182/blood-2019-122374.

Ruella M, Barrett DM, Shestova O, Perazzelli J, Posey AD, Hong SJ, Kozlowski M, Lacey SF, Melenhorst JJ, June CH, Gill S.: A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor positive cells. Blood Page: pii: blood.2019001859, Nov 2019 Notes: doi: 10.1182/blood.2019001859. [Epub ahead of print]

Alfred L. Garfall, Ehren Dancy, Adam D. Cohen, Wei-Ting Hwang, Joseph A. Fraietta, Megan M. Davis, Bruce L Levine, Don L. Siegel, Edward A. Stadtmauer, Dan T. Vogl, Adam Waxman, Aaron P. Rapoport, Michael C. Milone, Carl H. June, and J. Joseph Melenhorst: T cell phenotypes associated with effective CAR T cell therapy in post-induction versus relapsed multiple myeloma. Blood Advances 3(19): 2812, Oct 2019.

Xu J, Sai H, Li Y, Jordan AC, McGettigan SE, Chen JH, Bedoya F, Fraietta JA, Gladney WL, Melenhorst JJ*, Beatty GL*. * co-senior authors: Peripheral blood T cell fitness is diminished in patients with pancreatic carcinoma but can be improved with homeostatic cytokines. Cell Mol Gastroenterol Hepatol Page: pii: S2352-345X(19)30096-7, Aug 2019 Notes: doi: 10.1016/j.jcmgh.2019.07.008. [Epub ahead of print]

back to top
Last updated: 03/18/2020
The Trustees of the University of Pennsylvania